In a significant policy shift, the FDA has eliminated special protocols for a class of cancer treatments known as CAR T-cell therapies. This opens the door for more hospitals to offer them and more patients to benefit.
Until now, some of the most powerful cancer treatments in the world were limited to just a handful of hospitals. Patients had to travel long distances and stay close to treatment centers for weeks. Now that’s changing. The FDA has just removed key access limitations, allowing more hospitals to offer cutting-edge therapies that use a patient’s own white blood cells to fight cancer.
These personalized immunotherapies were once scarce, only available at certified hospitals where potential side effects were tracked. But they will now be easier to access.
These six therapies are made from the patients’ own (autologous) white blood cells (T-cells) modified with chimeric antigen receptors (CARs) and infused back into a patient to attack a specific cancer. The cutting-edge technology initially required elevated safety protocols, but now that clinicians are more familiar with the treatments and their potential side effects, the FDA has loosened restrictions so more patients can access them.
Post-treatment monitoring requirements were also scaled back, so patients who previously had to stay near a treatment facility for four weeks may be allowed to go home after just two weeks.
A special hospital-level certification is no longer required for autologous CAR T-cell therapy, especially now that clinicians know what to watch for. The risks and side effects of any drug are communicated to patients through consent forms, boxed warnings and product labeling. Manufacturers of each therapy will continue to monitor patient outcomes for at least 15 years.
CAR T therapies provide clinical benefits, but so far have reached only a fraction of eligible patients. Part of this gap can be explained by REMS, which monitors safety and efficacy, but requires significant amounts of administrative burden. With that safety baseline now established, reducing regulatory delays shows the FDA is committed to accelerating treatment timelines.
The FDA’s new approach could help ensure these innovative therapies reach the patients who need them—without unnecessary delays.
